About this trial
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and is the primary cause of cervical cancer. According to World Health Organization (WHO) systems, there were approximately 660,000 new cases of cervical cancer and 350,000 deaths in 2022. In Turkey, the prevalence of cervical cancer was reported as 8,761 in the last five years. HPV vaccines are safe and effective in preventing HPV transmission and cancer and are included in 147 national immunization programs; However, they have not yet been included in the national immunization program in Turkey. The WHO has reissued a regional strategy to eliminate cervical cancer by 2030, which includes vaccinating 90% of girls by age 15, screening 70% of women between the ages of 35 and 45, and increasing the treatment of 90% of precancerous lesions and invasive cervical cancer. The HPV vaccine provides the highest protection before the onset of sexual activity, and ACIP recommends routine vaccination of all 11-12-year-olds (starting at age 9). Catch-up vaccination is recommended for individuals up to age 26 who have not been previously vaccinated. Gardasil and Cervarix vaccines have been licensed in Turkey since 2007; However, vaccination rates are limited by the vaccine not being covered by social security, its cost, the number of doses, and low parental awareness. The safety of HPV vaccines is regularly monitored by international organizations, with approximately 1.7 cases of anaphylaxis per million doses administered.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Parent must be between 18-49 years old
Parent must be a child aged 11-18
Parent must not have hearing or speech problems
Parent must be able to read and write in Turkish
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
Education about vaccination
BehavioralParents of children eligible for the HPV vaccine will have their knowledge of HPV assessed and will receive education about the HPV vaccine. Following the education, the parents' knowledge levels and vaccination inclinations will be re-evaluated.
Treatment groups
Trial outcomes
Primary outcomes
the human papillomavirus knowledge scale
General HPV knowledge", with 16 questions on the subjects' general knowledge of HPV. The second subscale, "HPV testing knowledge", has six items related to HPV screening tests. The third subscale, "HPV vaccine knowledge" consists of seven items regarding HPV vaccine information. "HPV vaccine availability" items, the independent HPV-KS subscale, is organized in three different ways for the HPV vaccine program, which is conducted in three countries (the UK, the US, and Australia) where the scale is applied. The independent subscale can be modified to align with each country's HPV vaccine policy. Participants mark each item of the HPV-KS as "Yes", "No", and "I don't know". In the evaluation phase, each correct answer is scored as "1", and wrong answers and "I don't know" statements are scored as "0". The total HPV-KS score may be between "0 and 35". Higher scores indicate a thorough understanding of HPV general knowledge, HPV screening tests, and the HPV vaccine.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.